2018 Raynauds Disease Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Raynauds Disease Market
Raynauds Disease refers to a vascular condition that affects the blood flow to small tissues such as the ones in hands and toes. Around 20 to 25 million people are affected by Raynauds Disease in the US.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Raynauds Disease pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Raynauds Disease pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Raynauds Disease pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Raynauds Disease pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Raynauds Disease pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Raynauds Disease pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 RAYNAUDS DISEASE PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Raynauds Disease Pipeline Snapshot
2.3 Raynauds Disease Pipeline by Phase
2.4 Raynauds Disease Pipeline by Company
2.5 Raynauds Disease Pipeline by Mechanism of Action
3 RAYNAUDS DISEASE- COMPANY WISE PIPELINE ANALYSIS
Allergan Plc
Apricus Biosciences, Inc.
Bayer AG
Exodos Life Sciences Limited Partnership
Pfizer Inc.
4 RAYNAUDS DISEASE R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN RAYNAUDS DISEASE PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 RAYNAUDS DISEASE PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Raynauds Disease Pipeline Snapshot
2.3 Raynauds Disease Pipeline by Phase
2.4 Raynauds Disease Pipeline by Company
2.5 Raynauds Disease Pipeline by Mechanism of Action
3 RAYNAUDS DISEASE- COMPANY WISE PIPELINE ANALYSIS
Allergan Plc
Apricus Biosciences, Inc.
Bayer AG
Exodos Life Sciences Limited Partnership
Pfizer Inc.
4 RAYNAUDS DISEASE R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN RAYNAUDS DISEASE PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Raynauds Disease Pipeline by Phase, H2- 2018
Figure 2: Raynauds Disease Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Raynauds Disease Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
Figure 1: Raynauds Disease Pipeline by Phase, H2- 2018
Figure 2: Raynauds Disease Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Raynauds Disease Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
LIST OF TABLES
Raynauds Disease Pipeline by Phase, H2- 2018
Raynauds Disease Pipeline by Companies, H2- 2018
Raynauds Disease Pipeline by Mechanism of Action, H2- 2018
Table 1: Allergan Plc Raynauds Disease Pipeline Drugs, H2- 2018
Table 2: Apricus Biosciences, Inc. Raynauds Disease Pipeline Drugs, H2- 2018
Table 3: Bayer AG Raynauds Disease Pipeline Drugs, H2- 2018
Table 4: Exodos Life Sciences Limited Partnership Raynauds Disease Pipeline Drugs, H2- 2018
Table 5: Pfizer Inc. Raynauds Disease Pipeline Drugs, H2- 2018
Raynauds Disease Pipeline by Phase, H2- 2018
Raynauds Disease Pipeline by Companies, H2- 2018
Raynauds Disease Pipeline by Mechanism of Action, H2- 2018
Table 1: Allergan Plc Raynauds Disease Pipeline Drugs, H2- 2018
Table 2: Apricus Biosciences, Inc. Raynauds Disease Pipeline Drugs, H2- 2018
Table 3: Bayer AG Raynauds Disease Pipeline Drugs, H2- 2018
Table 4: Exodos Life Sciences Limited Partnership Raynauds Disease Pipeline Drugs, H2- 2018
Table 5: Pfizer Inc. Raynauds Disease Pipeline Drugs, H2- 2018
